Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the ...

Cannabinoid CB1 antagonists have been investigated for possible treatment of e.g. obesity-related disorders. However, clinical application was halted due to their symptoms of...大麻素CB1受体拮抗剂（Cannabinoid CB1 antagonists）已被研究用于潜在治疗例如肥胖相关病症等适应症。然而，因该类药物引发的相关症状……，其临床应用已被暂停。